MCID: PRT037
MIFTS: 64

Pertussis malady

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Pertussis

Aliases & Descriptions for Pertussis:

Name: Pertussis 12 50 56 3 3 14 69
Whooping Cough 12 50 56 41 3 42 14
Bordetella Infections 42 69
Whooping Cough Due to Unspecified Organism 69
Bordetella Pertussis Infection 50
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

56
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
SNOMED-CT 64 26484003
Orphanet 56 ORPHA1489
MESH via Orphanet 43 D014917
UMLS via Orphanet 70 C0043167
ICD10 via Orphanet 34 A37.0 A37.1 A37.8 more
UMLS 69 C0006015

Summaries for Pertussis

MedlinePlus : 41 whooping cough is an infectious bacterial disease that causes uncontrollable coughing. the name comes from the noise you make when you take a breath after you cough. you may have choking spells or may cough so hard that you vomit. anyone can get whooping cough, but it is more common in infants and children. it's especially dangerous for infants. the coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. to make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the u.s. now most cases are prevented by vaccines. if you have whooping cough, treatment with antibiotics may help if given early. centers for disease control and prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to hepatitis and measles, and has symptoms including coughing, fever and pruritus. An important gene associated with Pertussis is GNA14 (G Protein Subunit Alpha 14), and among its related pathways/superpathways are Pertussis and Signaling by GPCR. The drugs Montelukast and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and monocytes, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A commensal bacterial infectious disease that results_in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

Wikipedia : 71 Pertussis (also known as whooping cough or 100-day cough) is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.6 IL10 IL6 TNF
2 measles 30.2 IL1B IL6 MAPK1 TNF
3 nasopharyngitis 29.9 IL1B IL6 TNF
4 tuberculosis 29.5 IL10 IL1B IL6 TNF
5 neuropathy 29.4 IL1B IL6 TLR4 TNF
6 diphtheria 11.3
7 bordetella parapertussis whooping cough 10.8
8 tetanus 10.7
9 influenza 10.4
10 haemophilus influenzae 10.3
11 intussusception 10.3 IL1B TNF
12 ethmoid sinus cancer 10.3 IL1B JUN TLR4
13 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
14 megaloblastic anemia 10.3 IL10 IL1B TLR4
15 isolated growth hormone deficiency 10.3 IL1B JUN TLR4
16 hepatitis b 10.2
17 larynx leiomyoma 10.2 IL1B IL6 TLR4
18 gastric leiomyoma 10.2 IL1B IL6 TLR4
19 polyneuropathy in collagen vascular disease 10.2 FOS IL6 JUN
20 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 TNF
21 ovarian cystic teratoma 10.2 IL1B TLR4 TNF
22 aortic coarctation 10.2 IL6 TLR4 TNF
23 abnormal retinal correspondence 10.2 IL10 TLR4 TNF
24 childhood electroclinical syndrome 10.2 IL10 IL1B IL6
25 poliomyelitis 10.2
26 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
27 senile reticular retinal degeneration 10.2 IL10 IL1B TNF
28 x-linked intellectual disability, shashi type 10.2 GNA11 GNAQ
29 parasitic ichthyosporea infectious disease 10.2 ITGAM TLR4 TNF
30 cicatricial lagophthalmos 10.2 IL6 MAPK1 TNF
31 anal paget's disease 10.2 IL1B IL6 TNF
32 usher syndrome, type 2a 10.2 IL10 IL6 TLR4
33 crohn's colitis 10.2 IL6 TLR4 TNF
34 congenital hypothyroidism 10.2 CALM1 IL10 TNF
35 bipolar i disorder 10.2 IL1B IL6 TNF
36 human immunodeficiency virus infectious disease 10.2 IL1B IL6 TNF
37 tinea capitis 10.2 IL1B IL6 TNF
38 dextrocardia 10.2 IL1B IL6 TNF
39 grix blankenship peterson syndrome 10.2 ITGAM ITGB2 TNF
40 steroid dehydrogenase deficiency dental anomalies 10.2 IL1B IL6 TNF
41 urea cycle disorder 10.2 IL10 IL1B IL6
42 transient tic disorder 10.2 IL10 IL6 TNF
43 acquired thrombocytopenia 10.2 IL1B IL6 TNF
44 benign neonatal seizures 10.2 IL1B IL6 TNF
45 cyclosporiasis 10.2 IL10 IL6 TNF
46 mineral metabolism disease 10.2 IL1B IL6 TNF
47 trichomalacia 10.2 IL10 IL6 TNF
48 migraine with aura 10.2 IL1B IL6 TNF
49 phlyctenulosis 10.2 IL10 IL6 TNF
50 conduct disorder 10.2 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


coughing, fever, pruritus, snoring

MGI Mouse Phenotypes related to Pertussis:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.44 MAPK1 MAPK10 OPRM1 TLR4 TNF VIP
2 hematopoietic system MP:0005397 10.43 MAPK1 MAPK10 OPRM1 TLR4 TNF FOS
3 behavior/neurological MP:0005386 10.41 MAPK1 MAPK10 OPRM1 TLR4 TNF VIP
4 immune system MP:0005387 10.37 FOS GNA11 GNAI1 GNAQ IL10 IL1B
5 cardiovascular system MP:0005385 10.34 GNA11 GNAQ IL10 IL1B IL6 ITGB2
6 cellular MP:0005384 10.29 TNF FOS IL10 IL6 ITGAM ITGB2
7 integument MP:0010771 10.29 FOS GNA11 GNAQ GNAZ IL10 IL1B
8 mortality/aging MP:0010768 10.28 FOS GNA11 GNAQ GNAZ IL10 IL1B
9 endocrine/exocrine gland MP:0005379 10.24 GNAQ IL10 IL6 JUN MAPK1 OPRM1
10 nervous system MP:0003631 10.24 IL6 ITGAM JUN MAPK1 MAPK10 OPRM1
11 normal MP:0002873 10.02 FOS GNA11 GNA15 GNAQ IL10 ITGB2
12 liver/biliary system MP:0005370 10 GNA11 IL10 IL6 JUN MAPK1 TLR4
13 neoplasm MP:0002006 9.95 FOS IL10 IL1B IL6 MAPK1 TLR4
14 reproductive system MP:0005389 9.91 MAPK1 OPRM1 TLR4 TNF VIP FOS
15 respiratory system MP:0005388 9.81 GNA11 GNAQ IL10 IL6 JUN MAPK1
16 skeleton MP:0005390 9.73 FOS GNA11 GNAI1 GNAQ IL10 IL1B
17 vision/eye MP:0005391 9.23 FOS IL10 IL6 ITGB2 JUN MAPK1

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Anti-Asthmatic Agents Phase 4
8 Hormone Antagonists Phase 4,Phase 3
9 Hormones Phase 4,Phase 3
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
11 Leukotriene Antagonists Phase 4
12 Respiratory System Agents Phase 4
13 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
14 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
15 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
17 Protective Agents Phase 4,Phase 3,Phase 2
18 Antitoxins Phase 4,Phase 3
19 Diphtheria Antitoxin Phase 4,Phase 3
20 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
21 Antacids Phase 4,Phase 3,Phase 2
22 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
24 Anticoagulants Phase 4,Phase 3,Phase 2
25 Antidotes Phase 4,Phase 3,Phase 2
26 Calcium, Dietary Phase 4,Phase 3,Phase 2
27 Chelating Agents Phase 4,Phase 3,Phase 2
28 Iron Chelating Agents Phase 4,Phase 3,Phase 2
29 Pentetic Acid Phase 4,Phase 3,Phase 2
30 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
31 PENTA Phase 4,Phase 3,Phase 2
32 BCG Vaccine Phase 4,Phase 2
33 Analgesics Phase 4,Phase 3,Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 3
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4
37 Antipyretics Phase 4,Phase 3
38 Antirheumatic Agents Phase 4
39 Cyclooxygenase Inhibitors Phase 4
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
41
Deferiprone Approved Phase 3 30652-11-0 2972
42
Aluminum hydroxide Approved Phase 3,Phase 2 21645-51-2
43
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
44
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
45
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
46 gamma-Globulins Phase 3
47 Immunoglobulins, Intravenous Phase 3
48 Rho(D) Immune Globulin Phase 3
49 Hemagglutinins Phase 3,Phase 2
50 Cathartics Phase 3

Interventional clinical trials:

(show top 50) (show all 444)
id Name Status NCT ID Phase
1 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
2 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
3 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
4 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4
5 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
6 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
7 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
8 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
9 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
10 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
11 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
12 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
13 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
14 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4
15 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
16 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
17 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
18 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
19 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
20 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
21 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
22 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
23 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
24 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
25 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
26 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
27 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
28 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
29 Pertussis and Meningitis C Concomitant Vaccination in Adolescents Completed NCT02526394 Phase 4
30 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
31 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
32 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
33 Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With VAXELIS or INFANRIX Hexa Completed NCT02759354 Phase 4
34 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
35 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
36 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
37 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
38 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
39 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
40 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
41 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
42 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
43 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
44 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
45 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
46 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4
47 A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers Completed NCT01298544 Phase 4
48 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
49 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. Completed NCT01694108 Phase 4
50 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: whooping cough

Genetic Tests for Pertussis

Anatomical Context for Pertussis

MalaCards organs/tissues related to Pertussis:

39
Testes, T Cells, Monocytes, Neutrophil, Endothelial, Heart, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

18
Respiratory Tract

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 1145)
id Title Authors Year
1
Risk of Pertussis in Relation to Degree of Prematurity in Children < 2 Years of Age. ( 28067717 )
2017
2
Impact of age and vaccination history on long-term serological responses after symptomatic B. pertussis infection, a high dimensional data analysis. ( 28091579 )
2017
3
Emerging Bordetella pertussis Strains Induce Enhanced Signaling of Human Pattern Recognition Receptors TLR2, NOD2 and Secretion of IL-10 by Dendritic Cells. ( 28076445 )
2017
4
A New Vaccine Delivery Vehicle and Adjuvant Candidate: Bordetella Pertussis Inactivated Whole Cells Entrapped in Alginate Microspheres. ( 28079006 )
2017
5
Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. ( 28081971 )
2017
6
Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years. ( 28017441 )
2017
7
Assessing the social and environmental determinants of pertussis epidemics in Queensland, Australia: a Bayesian spatio-temporal analysis. ( 28091337 )
2017
8
Immune persistence after pertussis vaccination. ( 28045580 )
2017
9
Population-Based Pertussis Incidence and Risk Factors in Infants Less Than 6 Months in Nepal. ( 28073985 )
2017
10
The Timing of Pertussis Cases in Unvaccinated Children in an Outbreak Year: Oregon 2012. ( 28088399 )
2017
11
Estimating Pertussis Susceptibility Among 0-23-Month-Old Children in the United States. Using National Immunization Survey (NIS) 2013. ( 28060041 )
2017
12
Ric-8A-mediated stabilization of the trimeric G protein subunit GI+i is inhibited by pertussis toxin-catalyzed ADP-ribosylation. ( 28082199 )
2017
13
Risk factors for pertussis in adults and teenagers in England. ( 28065204 )
2017
14
Characteristics of Bordetella pertussis infection among infantsand children admitted to paediatric intensive care units in Greece: A multicentre, 11-year study. ( 28058755 )
2017
15
Complete Genome Sequence of Bordetella pertussis Strain VA-190 Isolated from a Vaccinated 10-Year-Old Patient with Whooping Cough. ( 27634997 )
2016
16
Effectiveness of prenatal Tdap vaccination on pertussis severity in infants. ( 27624956 )
2016
17
Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. ( 26899377 )
2016
18
Pertussis leukocytosis: mechanisms, clinical relevance and treatment. ( 27609461 )
2016
19
A novel high-throughput assay to quantify the vaccine-induced inhibition of Bordetella pertussis adhesion to airway epithelia. ( 27633511 )
2016
20
Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1I^ production by myeloid cells. ( 27189410 )
2016
21
Effectiveness of acellular pertussis vaccination during childhood (<7A years of age) for preventing pertussis in household contacts 1-9A years old in Catalonia and Navarra (Spain). ( 27612470 )
2016
22
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. ( 26803328 )
2016
23
Comparing Seasonal Pattern of Laboratory Confirmed Cases of Pertussis with Clinically Suspected Cases. ( 27169013 )
2016
24
The multifaceted RisA regulon of Bordetella pertussis. ( 27620673 )
2016
25
Direct molecular typing of Bordetella pertussis from nasopharyngeal specimens in China in 2012-2013. ( 27146879 )
2016
26
Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. ( 27212461 )
2016
27
Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. ( 27557706 )
2016
28
Promoting Adult Pertussis Vaccination in the Workplace. ( 27217084 )
2016
29
Effect of pertussis toxin pretreated centrally on blood glucose level induced by stress. ( 27610033 )
2016
30
Differential preference for pertussis and poliomyelitis vaccines in urban versus rural parents in Guatemala. ( 27095889 )
2016
31
Clinical Manifestations and Molecular Characterization of Pertactin-deficient and Pertactin-producing Bordetella pertussis in Children, Philadelphia 2007 - 2014. ( 27624959 )
2016
32
Parents as source of pertussis transmission in hospitalized young infants. ( 27614887 )
2016
33
Sex-differential effects on mortality of BCG and diphtheria-tetanus-pertussis vaccines in a rural area with high vaccination coverage: observational study from Senegal. ( 27738283 )
2016
34
Comparisons of the effect of naturally acquired maternal pertussis antibodies and antenatal vaccination induced maternal tetanus antibodies on infant's antibody secreting lymphocyte responses and circulating plasma antibody levels. ( 27176823 )
2016
35
Prevalence of Pertussis Antibodies in Maternal Blood, Cord Serum, and Infants From Mothers With and Those Without Tdap Booster Vaccination During Pregnancy in Argentina. ( 28040688 )
2016
36
Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-acellular Pertussis Vaccine in Mice. ( 28011915 )
2016
37
Bayesian Correction of Misclassification of Pertussis in Vaccine Effectiveness Studies: How Much Does Underreporting Matter? ( 27188939 )
2016
38
Elevated Pertussis Reporting in Response to 2011-2012 Outbreak, New York City, New York, USA. ( 27191867 )
2016
39
Undervaccination with diphtheria, tetanus, and pertussis vaccine: National trends and association with pertussis risk in young children. ( 27858500 )
2016
40
Association of Vitamin D Receptor Polymorphism with Susceptibility to Symptomatic Pertussis. ( 26894582 )
2016
41
Tetanus, diphtheria, and acellular pertussis vaccination among women of childbearing age-United States, 2013. ( 27372388 )
2016
42
Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine. ( 27038131 )
2016
43
Thermal Unfolding of the Pertussis Toxin S1 Subunit Facilitates Toxin Translocation to the Cytosol by the Mechanism of Endoplasmic Reticulum-Associated Degradation. ( 27647866 )
2016
44
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. ( 27171114 )
2016
45
Using age-stratified incidence data to examine the transmission consequences of pertussis vaccination. ( 27663785 )
2016
46
Immune Thrombocytopenia Following Diphtheria Pertussis- Tetanus and Oral Polio Vaccine. ( 27771689 )
2016
47
Morbidity and mortality risk factors of pertussis in pediatrics. ( 27646512 )
2016
48
Pertussis Incidence by Time, Province and Age Group in Iran, 2006-2011. ( 28028509 )
2016
49
Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States. ( 27188951 )
2016
50
Evaluation of outbreak response immunization in the control of pertussis using agent-based modeling. ( 27602299 )
2016

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to KEGG:

37
id Name Kegg Source Accession
1 Pertussis hsa05133

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 197)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.34 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ
2
Show member pathways
14.22 CALM1 FOS IL10 IL1B IL6 ITGAM
3
Show member pathways
14.05 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
4
Show member pathways
14.04 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
5
Show member pathways
13.93 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
6
Show member pathways
13.81 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
7
Show member pathways
13.73 CALM1 FOS GNA11 GNA14 GNA15 IL10
8
Show member pathways
13.66 CALM1 GNAI1 GNAQ IL1B IL6 JUN
9
Show member pathways
13.61 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
10
Show member pathways
13.57 CALM1 FOS IL10 IL1B IL6 ITGAM
11
Show member pathways
13.52 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
12
Show member pathways
13.51 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ
13
Show member pathways
13.5 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
14
Show member pathways
13.48 FOS IL10 IL1B IL6 JUN MAPK1
15
Show member pathways
13.46 CALM1 FOS GNAI1 IL6 JUN MAPK1
16
Show member pathways
13.41 CALM1 FOS GNA11 GNAI1 GNAQ GNAZ
17
Show member pathways
13.31 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ
18
Show member pathways
13.28 FOS GNA11 GNA14 GNA15 GNAI1 IL6
19
Show member pathways
13.28 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
20
Show member pathways
13.27 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
21
Show member pathways
13.22 CALM1 FOS IL1B IL6 JUN MAPK1
22
Show member pathways
13.21 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
23
Show member pathways
13.2 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
24
Show member pathways
13.17 CALM1 FOS IL6 JUN MAPK1 MAPK10
25
Show member pathways
13.12 FOS ITGAM ITGB2 JUN MAPK1 MAPK10
26
Show member pathways
13.12 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
27
Show member pathways
13.1 CALM1 FOS GNA11 GNAI1 GNAQ JUN
28
Show member pathways
13.1 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
29
Show member pathways
13.06 FOS ITGAM ITGB2 JUN MAPK1 MAPK10
30
Show member pathways
13.06 CALM1 FOS GNA11 GNAI1 GNAQ GNAZ
31
Show member pathways
13.04 CALM1 FOS GNA11 GNAI1 ITGAM ITGB2
32
Show member pathways
13.03 FOS IL1B IL6 JUN MAPK1 MAPK10
33
Show member pathways
13.02 IL6 JUN MAPK1 MAPK10 TNF
34
Show member pathways
13.02 CALM1 GNA11 GNA14 GNA15 GNAI1 IL6
35
Show member pathways
12.99 FOS GNA11 GNA14 GNA15 GNAI1 GNAQ
36
Show member pathways
12.98 CALM1 FOS GNA11 GNAI1 GNAQ MAPK1
37
Show member pathways
12.95 CALM1 GNAI1 GNAQ ITGAM ITGB2 MAPK1
38
Show member pathways
12.93 CALM1 FOS GNA11 GNAI1 GNAQ GNAZ
39
Show member pathways
12.92 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
40 12.91 FOS GNA11 GNAI1 GNAQ IL6 JUN
41 12.9 FOS IL1B JUN MAPK1 MAPK10 TNF
42
Show member pathways
12.89 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
43
Show member pathways
12.88 CALM1 FOS GNA15 IL10 JUN MAPK1
44
Show member pathways
12.86 FOS IL1B JUN MAPK1 MAPK10 TNF
45
Show member pathways
12.85 CALM1 IL1B IL6 TLR4 TNF
46
Show member pathways
12.84 FOS IL10 IL1B IL6 JUN MAPK1
47
Show member pathways
12.83 CALM1 FOS GNA11 GNAQ IL1B JUN
48
Show member pathways
12.8 FOS IL10 IL1B IL6 MAPK1 TNF
49
Show member pathways
12.8 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
50
Show member pathways
12.79 CALM1 FOS JUN MAPK1 MAPK10 TNF

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ
2 extracellular exosome GO:0070062 9.96 CALM1 GNA11 GNA14 GNAI1 GNAQ GNAZ
3 heterotrimeric G-protein complex GO:0005834 9.1 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
4 transcription factor AP-1 complex GO:0035976 8.96 FOS JUN

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 Fc-epsilon receptor signaling pathway GO:0038095 9.99 CALM1 FOS JUN MAPK1 MAPK10
2 inflammatory response GO:0006954 9.98 FOS IL10 IL1B IL6 ITGB2 TLR4
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 IL6 JUN OPRM1 TLR4 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.95 IL10 IL6 TLR4 TNF
5 aging GO:0007568 9.95 FOS IL10 IL6 ITGB2 JUN
6 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.92 IL10 IL1B IL6 TNF
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 IL1B IL6 ITGB2 TLR4 TNF
8 response to glucocorticoid GO:0051384 9.89 IL10 IL6 TNF
9 positive regulation of JNK cascade GO:0046330 9.88 IL1B TLR4 TNF
10 response to mechanical stimulus GO:0009612 9.88 FOS IL6 JUN
11 response to cytokine GO:0034097 9.86 FOS IL6 JUN
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 IL6 JUN TNF
13 activation of MAPK activity GO:0000187 9.85 IL1B MAPK1 MAPK10 TLR4 TNF
14 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.84 GNAI1 GNAZ OPRM1
15 positive regulation of interferon-gamma production GO:0032729 9.83 IL1B TLR4 TNF
16 cellular response to reactive oxygen species GO:0034614 9.81 FOS JUN MAPK1
17 cellular response to cadmium ion GO:0071276 9.8 FOS JUN MAPK1
18 positive regulation of interleukin-8 production GO:0032757 9.79 IL1B TLR4 TNF
19 negative regulation of interleukin-6 production GO:0032715 9.79 IL10 TLR4 TNF
20 positive regulation of interleukin-6 production GO:0032755 9.78 IL1B IL6 TLR4 TNF
21 positive regulation of NF-kappaB import into nucleus GO:0042346 9.77 IL1B TLR4 TNF
22 positive regulation of chemokine production GO:0032722 9.76 IL6 TLR4 TNF
23 toll-like receptor 4 signaling pathway GO:0034142 9.75 ITGAM ITGB2 TLR4
24 platelet activation GO:0030168 9.73 GNA11 GNA14 GNA15 GNAQ IL6 MAPK1
25 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
26 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.72 GNA11 GNA14 GNA15 GNAI1 GNAZ
27 phototransduction, visible light GO:0007603 9.71 GNA11 GNAQ
28 negative regulation of lipid storage GO:0010888 9.71 IL6 TNF
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 IL1B MAPK1 TLR4 TNF
30 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.7 TLR4 TNF
31 entrainment of circadian clock GO:0009649 9.7 GNA11 GNAQ
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 IL1B TNF
33 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL10 TLR4
35 regulation of establishment of endothelial barrier GO:1903140 9.68 IL1B TNF
36 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
37 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.67 IL6 TNF
38 regulation of sequence-specific DNA binding transcription factor activity GO:0051090 9.67 FOS JUN MAPK1 MAPK10
39 positive regulation of fever generation GO:0031622 9.66 IL1B TNF
40 sequestering of triglyceride GO:0030730 9.65 IL1B TNF
41 cellular extravasation GO:0045123 9.65 ITGB2 TNF
42 receptor biosynthetic process GO:0032800 9.64 IL10 TNF
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 IL1B TNF
44 regulation of melanocyte differentiation GO:0045634 9.61 GNA11 GNAQ
45 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.46 GNA11 GNA14 GNA15 GNAQ
46 positive regulation of nitric oxide biosynthetic process GO:0045429 9.35 IL1B IL6 ITGB2 TLR4 TNF
47 response to lipopolysaccharide GO:0032496 9.23 FOS IL10 IL1B IL6 JUN MAPK1
48 signal transduction GO:0007165 10.28 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
49 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.22 FOS IL10 IL1B IL6 JUN TLR4
50 G-protein coupled receptor signaling pathway GO:0007186 10.15 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.85 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
2 GTPase activity GO:0003924 9.8 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
3 signal transducer activity GO:0004871 9.8 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
4 cytokine activity GO:0005125 9.76 IL10 IL1B IL6 TNF
5 G-protein coupled receptor binding GO:0001664 9.63 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
6 G-protein coupled serotonin receptor binding GO:0031821 9.43 GNAI1 GNAZ
7 G-protein beta/gamma-subunit complex binding GO:0031683 9.43 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
8 type 2A serotonin receptor binding GO:0031826 9.4 GNA11 GNAQ
9 guanyl nucleotide binding GO:0019001 9.1 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ

Sources for Pertussis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....